Objective: The mechanism of Schisandrin B on the proliferation and migration of airway smooth muscle cells (ASMCs) in asthmatic rats was explored.
| INTRODUCTION
Asthma is a chronic airway disorder, which is characterized by airflow obstruction, inflammation and airway hyperreactivity. 1 It affects 5%
of adults and 10% of children with continues rising prevalence. 2 There are many factors that can cause asthma, including exercise, infection, allergens, occupational exposures and smoking, 3 and the symptoms mainly include shortness of breath, wheezing, coughing and tightness of the chest. 4 Airway smooth muscle (ASM) has hyperplastic and hypertrophic characteristics, and it may be an important contributor to airflow obstruction, which leads to increased thickening and narrowing of airways. 5 ASM cells (ASMCs) is also associated with the inflammatory response in the airways through secreting proteases, cytokines and growth factors that can induce ASM phenotypic modulation.
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In addition to these symptoms, ASM in asthma is infiltrated by mast cells (MCs). 6 MCs can release a lot of pleiotropic autacoid mediators, proteases and cytokines that interact with smooth muscle cells and induce proliferation and contraction that can limit airway narrowing reversibility, 7 so it plays a significant role in the pathophysiology of asthma. 8 Researchers also thought the infiltration of ASM by MCs is one of the essential determinants of asthmatic phenotype. [9] [10] [11] Schisandrin B is one of the most commonly used lignans in
Chinese folk medicine, which is extracted from Schisandra chinensis Baill fruit. 12 It can be used for anti-hepatitis, anti-asthma, antiageing, antioxidant and treating myocardial disorders. 13 In 2015, Lv et al proved that Schisandrin B inhibited the proliferation of human lung adenocarcinoma A549 cells. 15 In 2016, Zhang et al 14 reported
Schisandrin B could inhibit the proliferation of ASMCs. Later, Jiang expression.
Here we demonstrate that Schisandrin B inhibits the proliferation and migration of ASMCs in asthmatic rats via mast cells, and further explain the reason for the changes of BCYRN1 expression in ASMCs of asthmatic rats.
| MATERIALS AND METHODS

| Animals and groups
All the experiments were performed at the department of Respiratory 
| Cell culture and stimulation
Mast cells and ASMCs were isolated from SD rats in accordance with the protocol approved by the Ethics Committee of People's Hospital
Affiliated to Zhengzhou University, and cultured as previously described. 23, 24 At confluence, ASMC cultures exhibited a typical "hill-and-valley" appearance. ASMC suspensions were seeded at a density of 1-5 × 10 5 cells/mL, and ASMCs were harvested for study when >95% of the cells displayed the characteristics of smooth muscle cells. MCs were harvested for the study when the concentration was >95%. Cells at passages 6-10 were used for all experiments.
Airway smooth muscle cells were pre-treated with dexamethasone (10 −7 mol/L) for 1 hour, then stimulated with 2.5% foetal bovine serum (FBS, Gibco) for 24 hour. MCs were stimulated by IgE (2.5 μg/mL) and goat anti-human IgE (1 μg/mL) (Calbiochem, CA) as previously described.
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| Measurements of cell viability, proliferation and migration
The viability and proliferation of ASMCs were detected by WST-1 assay and Roche real-time cell analyser (RTCA) DP assay. ASMCs were seeded into 96-well plates with DMEM containing 10% FBS.
ASMCs were arrested by removing serum for 24 hour, stimulated with PDGF-BB (25 ng/mL, Gibco) for 24 hour, added WST-1 directly to the culture wells and incubated for 120 minutes at 37°C.
Plates were read by a scanning multi-well spectrophotometer with a wavelength of 450 nm and a reference wavelength of 630 nm.
Percentage of viability was obtained by comparing OD values to
that of ASMCs in a control group. The ASMCs proliferation variation was obtained using the Roche RTCA DP assay by calculating the changes of ASMCs to baseline. Each experiment was repeated at least three times. 
| RNA pull-down assays
Biotin-labelled BCYRN1 was transcribed with the biotin RNA Labeling mix (Roche) and T7 or SP6 RNA polymerase, and purified with RNeasy
Mini Kit (QIAGEN). Then protein (1 mg) from ASMCs extracts was mixed with biotinylated RNA biotin-labelled RNAs (50 pmol), and incubated with streptavidin agarose beads (Invitrogen). The standard Western blotting technique was used for measuring proteins binding to the streptavidin-coupled dynabeads.
| Western blot
Protein concentrations were determined by BCA Protein Assay kit (Pierce Biotechnology). Western blot was performed according to standard procedures. The Ago 2 antibody against BCYRN1 was purchased from Abcam (Cambridge, United Kingdom) and used as the first primary antibody. The corresponding horseradish peroxidase-conjugated secondary antibody (Invitrogen) was incubated for 1 hour. Protein-antibody complexes were detected by the enhanced chemiluminescence system (ECL, Roche Molecular Biochemicals). β-actin (Invitrogen) was served as a control protein to quantify the expression of related proteins.
| Quantitative real-time PCR
RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's instructions. RNA was reverse transcribed using the SuperScript First Strand Synthesis System for RT-PCR (Invitrogen).
An ABI Prism 5700 Sequence Detection System (Applied Biosystems)
was used for reverse-transcription of total RNA and the subsequent Figure 1A ). There were significant differences in three different groups in both MCs and ASMCs (P < .01). BCYRN1 expression was up-regulated in ASMCs, and the expression in model group was lower than model + Schisandrin B group, which indicated that Schisandrin B reversed the expression of BCYRN1 ( Figure 1B ).
There were significant differences in three different groups in ASMCs (P < .01). These findings suggested that Schisandrin B up-regulated miR-150 expression and down-regulated BCYRN1 expression in asthma model rats.
| Schisandrin B reverses the expression of miR-150 in bronchial MCs
The 
| Schisandrin B reverses the expressions of miR-150 and BCYRN1 level in MV-induced ASMCs
According to Figure 3A , the expression of miR-150 in ASMCs was down-regulated after induced by MV, and Schisandrin B reversed 
| Schisandrin B inhibits the viability, proliferation and migration of MV-induced ASMCs
Next, we examined the effect of MVs on the viability, proliferation and migration of ASMCs. Viability, proliferation and migration of ASMCs were increased, and Schisandrin B reversed this effect ( Figure 4A-D ).
There were significant differences in ASMCs treated with or without Schisandrin B (P < .01). These data indicated that Schisandrin B played critical roles in inhibiting viability, proliferation and migration of ASMCs.
| Effect of miR-150 on BCYRN1 expression on MV-induced ASMCs
According to bioinformatics software, 11 direct combination sites were found between miR-150 and BCYRN1 ( Figure 5A ). We per- 
| DISCUSSION
Airway smooth muscle, as a producer of pro-and anti-inflammatory mediators, can affect apoptosis, proliferation and migration of ASMCs. 27 Abnormal ASMCs proliferation and migration in the airway cause increasing thickness of airway wall, participating in the development of airway remodelling of asthma. 19 Hence, it is necessary to study medicals that can effectively inhibit ASMC proliferation and migration in asthma research. In our previous study, we demonstrated that Schisandrin B attenuated the inspiratory and expiratory resistances in sensitized rats, and could inhibit ASMC proliferation and migration. 14 To clarify the molecular mechanism of Schisandrin B inhibiting ASMC proliferation and migration, we de- Previously study indicated that BCYRN1 promoted the proliferation and migration of ASMCs in asthma rats. In summary, these findings suggest that Schisandrin B up-regulated miR-150 expression and down-regulated BCYRN1, and BCYRN1 expression was inhibited by miR-150, which indicated that Schisandrin B could regulate BCYRN1 through miR-150. Although further investigations were needed for clinical applications, this study has provided basis for the important role of BCYRN1 in abnormal ASMCs proliferation and migration in asthma.
